SEC Form 4 · accession 0001567160-26-000009
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Gano
Officer — Chief Executive Officer · Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 5:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 11, 2026 | A | 6,275 | $0.00 | A | 157,266 | D | |
| Common Stock | Sep 11, 2026 | F | 3,386 | $156.22 | D | 153,880 | D | |
| Common Stock | Sep 11, 2026 | A | 1,842 | $0.00 | A | 155,722 | D | |
| Common Stock | Sep 11, 2026 | F | 994 | $156.22 | D | 154,728 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
- F2Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F3Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.